Evidence map›Paper›PMID 26504803›Full record

ArticleBioMed research international2015

miR-125b Suppresses Proliferation and Invasion by Targeting MCL1 in Gastric Cancer.

Shihua Wu, Feng Liu, Liming Xie, Yaling Peng, Xiaoyuan Lv, Yaping Zhu, Zhiwei Zhang, Xiusheng He

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 42 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. LINC00152 down-regulatedBioscience reports · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Gastric Cancer in the Era of Precision Medicine.Cellular and molecular gastroenterology and hepatology · 2017
    Review
  18. Senescence-Associated MicroRNAs.International review of cell and molecular biology · 2017
    Review
  19. Article
  20. Role of ARPC2 in Human Gastric Cancer.Mediators of inflammation · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Shihua WuCancer Research Institute, Key Laboratory of Cancer Cellular and Molecular Pathology of Hunan Provincial University, University of South China, Hengyang 421001, China ; Department of Pathology, Shaoyang Medical College, Shaoyang 422000, China.
Feng LiuGraduate Department, University of South China, Hengyang 421001, China.
Liming XieCancer Research Institute, Key Laboratory of Cancer Cellular and Molecular Pathology of Hunan Provincial University, University of South China, Hengyang 421001, China.
Yaling PengDepartment of Pathology, Shaoyang Medical College, Shaoyang 422000, China.
Xiaoyuan LvDepartment of Pathology, Shaoyang Medical College, Shaoyang 422000, China.
Yaping ZhuDepartment of Pathology, Shaoyang Medical College, Shaoyang 422000, China.
Zhiwei ZhangCancer Research Institute, Key Laboratory of Cancer Cellular and Molecular Pathology of Hunan Provincial University, University of South China, Hengyang 421001, China.
Xiusheng HeCancer Research Institute, Key Laboratory of Cancer Cellular and Molecular Pathology of Hunan Provincial University, University of South China, Hengyang 421001, China.
University of South China · CNShaoyang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Understanding the molecular mechanisms underlying gastric cancer progression contributes to the development of novel targeted therapies. In this study, we found that the expression levels of miR-125b were strongly downregulated in gastric cancer and associated with clinical stage and the presence of lymph node metastases. Additionally, miR-125b could independently predict OS and DFS in gastric cancer. We further found that upregulation of miR-125b inhibited the proliferation and metastasis of gastric cancer cells in vitro and in vivo. miR-125b elicits these responses by directly targeting MCL1 (myeloid cell leukemia 1), which results in a marked reduction in MCL1 expression. Transfection of miR-125b sensitizes gastric cancer cells to 5-FU-induced apoptosis. By understanding the function and molecular mechanisms of miR-125b in gastric cancer, we may learn that miR-125b has the therapeutic potential to suppress gastric cancer progression and increase drug sensitivity to gastric cancer.

Indexed as

AnimalsApoptosisBase SequenceCell Line, TumorCell ProliferationDown-RegulationFemaleFluorouracilHumansLymphatic MetastasisMaleMiceMice, Inbred BALB CMice, NudeMicroRNAsMiddle AgedFluorouracilMCL1 protein, humanMicroRNAsMIRN125 microRNA, humanMyeloid Cell Leukemia Sequence 1 ProteinRNA, MessengerRNA, Neoplasm

Identifiers

PMID26504803
PMCPMC4609369
OpenAlexW1939031110

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.